Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review
Research output: Contribution to journal › Review › Research › peer-review
Over the last decade, the discovery of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) has increased the treatment options for patients with type 2 diabetes mellitus (T2DM). GLP-1 RAs mimic the effects of native GLP-1, which increases insulin secretion, inhibits glucagon secretion, increases satiety and slows gastric emptying. This review evaluates the phase III trials for all approved GLP-1 RAs and reports that all GLP-1 RAs decrease HbA1c, fasting plasma glucose, and lead to a reduction in body weight in the majority of trials. The most common adverse events are nausea and other gastrointestinal discomfort, while hypoglycaemia is rarely reported when GLP-1 RAs not are combined with sulfonylurea or insulin. Treatment options in the near future will include co-formulations of basal insulin and a GLP-1 RA.
Original language | English |
---|---|
Journal | Expert Review of Clinical Pharmacology |
Volume | 9 |
Issue number | 2 |
Pages (from-to) | 241-65 |
Number of pages | 25 |
ISSN | 1751-2433 |
DOIs | |
Publication status | Published - 2016 |
- Animals, Blood Glucose, Diabetes Mellitus, Type 2, Glucagon, Glucagon-Like Peptide 1, Glucagon-Like Peptide-1 Receptor, Humans, Hypoglycemic Agents, Insulin, Journal Article, Review
Research areas
ID: 176702269